Nouvelles.droit.org

🕒
RSS JSON
her condition logicielle tavr autorité extreme ethereum weight bogus that products companies toxic market its case deal claims battle today clients bogo shocking proposed rosca medical jenavalve edwards ftc acquisition diversité mould devices
4 Résultats (1 - 4)
The Shocking Reality: Mum’s Battle with Toxic Mould Reveals Landlord’s Negligence (Business Today)
: Key Takeaways: Living Nightmare: A Mother’s Struggle with Toxic Mould Beverley McNally’s journey through the past five years has been marked by adversity and frustration as she battled against the insidious threat of toxic mould infiltrating her home. A devoted mother of two, Beverley faced unimaginable challenges as her family’s health and well-being were jeopardized by the relentless spread of mould. A Growing Menace: The Emergence of Toxic Mould What began as a minor leak in Beverley’s bathroom extractor fan burgeoned into a full-blown crisis, shrouding her Ealing townhouse in a veil of dampness and decay. As the mould crept The post The Shocking Reality: Mum’s Battle with Toxic Mould Reveals Landlord’s Negligence appeared first on Business Today
State of software diversity in ethereum (Faculté de droit Travaux récents)
: dc.contributor.author: Gonzalez Fernandez, Nadia dc.date.issued: 2026-10 dc.description.abstract: La diversité logicielle contribue à améliorer la fiabilité et la sécurité des systèmes depuis les années 1960, notamment gr'ce à des modèles dans lesquels une autorité centrale mandate et certifie des implémentations indépendantes. Au cours de la dernière décennie, Ethereum a déployé la diversité à grande échelle sous une forme nouvelle : 11 clients indépendants y coexistent sans être mandatés ni certifiés par une autorité centrale, tout en bénéficiant de la diversité déjà présente dans l’écosystème open source. Cette thèse étudie Ethereum comme un exemple de ce modèle émergent de diversité logicielle, en examinant son adoption, son étendue dans le code des clients et les défis qu’elle soulève. Nous combinons des entretiens semi-directifs avec sept contributeurs impliqués dans le développement, la coordination et le suivi de la diversité des clients, avec la première analyse statique complète de la chaîne d’appr[...]
First FTC ROSCA case challenges bogus BOGO and "free" claims (FTC USA Business Blog Posts)
: First FTC ROSCA case challenges bogus BOGO and "free" claims wfg-adm109 October 21, 2014 | 12:02PM First FTC ROSCA case challenges bogus BOGO and "free" claims By Lesley Fair It’s called ROSCA – the Restore Online Shoppers’ Confidence Act – and it prohibits marketers from charging consumers for an online transaction unless the marketer has clearly disclosed all material terms of the deal and received the consumer’s express informed consent. Your e-commerce clients will want to know about the FTC’s first ROSCA case , filed recently in Nevada. According to the lawsuit, Health Formulas, LLC and a tangle of related California- and Nevada-based companies and individuals – consumers may know them as Simple Pure Nutrition – pitched a variety of products for weight loss, muscle building, virility, and skin care. The defendants advertised diet supplements like Pure Green Coffee Bean Plus and RKG Extreme as a shortcut to drop the pounds: “Burn fat without diet or exercise,” “Extreme weight loss!” “Shed pounds fast!” “[...]
FTC Challenges Anticompetitive Medical Device Deal (Federal Trade Commission Concurrence communiqués)
: The Federal Trade Commission today moved to block medical device supplier Edwards Lifesciences Corp.’s (Edwards) proposed acquisition of JenaValve Technology, Inc. (JenaValve) due to concerns that the acquisition would limit patient access to lifesaving medical devices used to treat a potentially fatal heart condition. The FTC alleges that over the span of two days in July 2024, Edwards executed agreements to acquire both JenaValve and JC Medical, the two leading companies competing to bring to market transcatheter aortic valve replacement devices that treat a heart condition called aortic regurgitation (TAVR-AR devices). Edwards closed its acquisition of JC Medical in August 2024, and its proposed $945 million acquisition of JenaValve would combine the only two companies with ongoing clinical trials in the United States for a TAVR-AR device. The deal threatens to reduce competition in the TAVR-AR market, likely resulting in reduced innovation, diminished product quality, and potentially increased prices for[...]